AstraZeneca PLC provided earnings guidance for the fiscal 2022. Total Revenue from COVID-19 medicines is anticipated to decline by a low-to-mid twenties percentage, with an expected decline in sales of Vaxzevria being partially offset by growth in Evusheld sales. The majority of Vaxzevria revenue in 2022 is expected to come from initial contracts.

The Gross Margin from the COVID-19 medicines is expected to be lower than the Company average Total Revenue is expected to increase by a high teens percentage. Core EPS is expected to increase by a mid-to-high twenties percentage.